Novo Nordisk Unusual Options Activity For February 14

Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk.

Looking at options history for Novo Nordisk NVO we detected 21 trades.

If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 71% with bearish.

From the overall spotted trades, 3 are puts, for a total amount of $475,330 and 18, calls, for a total amount of $899,004.

Projected Price Targets

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $92.5 to $145.0 for Novo Nordisk during the past quarter.

Volume & Open Interest Trends

In today's trading context, the average open interest for options of Novo Nordisk stands at 1558.89, with a total volume reaching 3,034.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $92.5 to $145.0, throughout the last 30 days.

Novo Nordisk Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Where Is Novo Nordisk Standing Right Now?

• Currently trading with a volume of 3,575,443, the NVO's price is up by 0.43%, now at $120.51.
• RSI readings suggest the stock is currently may be overbought.
• Anticipated earnings release is in 78 days.

Expert Opinions on Novo Nordisk

Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $133.33333333333334.

• In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $140.
• In a cautious move, an analyst from Morgan Stanley downgraded its rating to Overweight, setting a price target of $120.
• Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Novo Nordisk with a target price of $140.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.